BioLineRx Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 38
Employees
  • Stock Symbol
  • BLRX
Stock Symbol
  • Investments
  • 4
  • Share Price
  • $0.10
  • (As of Monday Closing)

BioLineRx General Information

Description

BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Other Pharmaceuticals and Biotechnology
Stock Exchange
TAE
Primary Office
  • Modi'in Technology Park
  • 2 HaMa'ayan Street
  • Modi'in 7177871
  • Israel
+972 00-000-0000

BioLineRx Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioLineRx Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.10 $0.11 $0.09 - $0.42 $77.9M 715M 1.04M -$0.08

BioLineRx Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 69,057 47,329 7,202 15,010
Revenue 0 0 0 0
EBITDA (33,173) (27,853) (23,454) (22,846)
Net Income (34,738) (30,021) (25,446) (22,962)
Total Assets 86,905 47,290 53,567 56,233
Total Debt 5,422 7,684 10,455 8,733
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioLineRx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioLineRx‘s full profile, request access.

Request a free trial

BioLineRx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its develop
Biotechnology
Modi'in, Israel
38 As of 2020
00000
000000000 00000

0000000

is nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dol
0000 000000000
Kulmbach, Germany
00 As of 0000
000000000000

0000000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse c
0000000000000
Framingham, MA
0 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioLineRx Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Axolabs Private Equity-Backed Kulmbach, Germany 00 000000000000
0000000 0000000000 Corporation Framingham, MA 0 000.00 000000000 000.00
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
0000000 0000000000 Formerly PE-Backed Cambridge, MA 000 00000 000000000
You’re viewing 5 of 17 competitors. Get the full list »

BioLineRx Patents

  • 66

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 5

    Pending

  • 000

    Expiring in next 12 mo

BioLineRx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3911353-A1 Specific combination therapy for treatment of pancreatic cancer Pending 17-Jan-2019 000000000
US-20210338767-A1 Methods of selecting treatment for cxcr4-associated cancer Pending 25-Sep-2018 000000000
EP-3856225-A1 Methods of selecting treatment for cxcr4-associated cancer Pending 25-Sep-2018 000000000
AU-2019277908-A1 Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors Pending 27-May-2018 00000000000
CA-3099383-A1 Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors Pending 27-May-2018 A61K31/7032
To view BioLineRx’s complete patent history, request access »

BioLineRx Executive Team (10)

Name Title Board Seat Contact Info
Philip Serlin Chief Executive Officer
Mali Zeevi Chief Financial Officer, Finance
Ella Sorani Executive
Abi Vainstein-Haras MD Chief Medical Officer
You’re viewing 4 of 10 executive team members. Get the full list »

BioLineRx Board Members (8)

Name Representing Role Since
Aharon Schwartz Ph.D Self Chairman & Board Member 000 0000
Avraham Molcho MD Self Board Member 000 0000
BJ Bormann Ph.D Self Board Member 000 0000
Michael Anghel Ph.D Self Board Member 000 0000
Nurit Benjamini Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

BioLineRx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioLineRx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioLineRx‘s full profile, request access.

Request a free trial

BioLineRx Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 03-Oct-2018 000000000 Drug Discovery 000000 00
0000000000 23-Mar-2017 0000000000 00.000 Biotechnology 000000 00
0000000 25-Aug-2016 00000 0000 Drug Discovery
Biokine Therapeutics Merger/Acquisition Drug Discovery 000000 00
To view BioLineRx’s complete investments and acquisitions history, request access »

BioLineRx Subsidiaries (1)

Company Name Industry Location Founded
0000000 0000000000 Drug Discovery Rehovot, Israel 0000
To view BioLineRx’s complete subsidiaries history, request access »